Pathophysiology of chronic kidney disease-mineral and bone disorder

被引:35
|
作者
Mac Way, Fabrice [1 ,2 ,3 ]
Lessard, Myriam [1 ,2 ,4 ]
Lafage-Proust, Marie-Helene [1 ,2 ]
机构
[1] Univ Lyon, INSERM, U1059, F-42023 St Etienne 2, France
[2] CHU St Etienne, F-42055 St Etienne 2, France
[3] Hotel Dieu Quebec, Nephrol, Quebec City, PQ G1R 2J6, Canada
[4] Hop Sacre Coeur Montreal, Ouest Montreal, PQ H4J 1C5, Canada
关键词
Parathyroid hormone; FGF23; Bone biopsy; Bone turnover; Osteomalacia; Secondary hyperparathyroidism; HYPERPLASTIC PARATHYROID-GLANDS; RENAL OSTEODYSTROPHY; CKD PATIENTS; SECONDARY HYPERPARATHYROIDISM; DEPRESSED EXPRESSION; DOWN-REGULATION; RECEPTOR; CALCIUM; FGF23; PTH;
D O I
10.1016/j.jbspin.2012.09.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease (CKD) alters the metabolism of several minerals, thereby inducing bone lesions and vessel-wall calcifications that can cause functional impairments and excess mortality. The histological bone abnormalities seen in CKD, known as renal osteodystrophy, consist of alterations in the bone turnover rate, which may be increased (osteitis fibrosa [OF]) or severely decreased (adynamic bone disease [AD]); abnormal mineralization (osteomalacia [OM]), and bone loss. Secondary hyperparathyroidism is related to early phosphate accumulation (responsible for FGF23 overproduction by bone tissue), decreased calcitriol production by the kidneys, and hypocalcemia. Secondary hyperparathyroidism is associated with OF. Other factors that affect bone include acidosis, chronic inflammation, nutritional deficiencies, and iatrogenic complications. (C) 2012 Published by Elsevier Masson SAS on behalf of the Societe Francaise de Rhumatologie.
引用
收藏
页码:544 / 549
页数:6
相关论文
共 50 条
  • [41] Pharmacotherapy of chronic kidney disease and mineral bone disorder
    Barreto, Fellype Carvalho
    de Oliveira, Rodrigo Azevedo
    Oliveira, Rodrigo Bueno
    Jorgetti, Vanda
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (17) : 2627 - 2640
  • [42] Role of sclerostin in the pathogenesis of chronic kidney disease-mineral bone disorder
    Asamiya Y.
    Tsuchiya K.
    Nitta K.
    Renal Replacement Therapy, 2 (1) : 1 - 8
  • [43] R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)
    Moe, Sharon M.
    Seifert, Mark F.
    Chen, Neal X.
    Sinders, Rachel M.
    Chen, Xianming
    Duan, Dana
    Henley, Charles
    Martin, Dave
    Gattone, Vincent H., II
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (08) : 2371 - 2377
  • [44] Biochemical abnormalities in chronic kidney disease-mineral bone disease
    Negrea L.A.
    Clinical Reviews in Bone and Mineral Metabolism, 2012, 10 (3): : 149 - 162
  • [45] The role of Fibroblast Growth Factor 23 in chronic kidney disease-mineral and bone disorder
    Diniz, Hugo
    Frazao, Joao M.
    NEFROLOGIA, 2013, 33 (06): : 835 - 844
  • [46] Review article: Chronic kidney disease-mineral bone disorder: Have we got the assays right?
    Zidehsarai, Miriam P.
    Moe, Sharon M.
    NEPHROLOGY, 2009, 14 (04) : 374 - 382
  • [47] Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder
    Goto, Shunsuke
    Komaba, Hirotaka
    Fukagawa, Masafumi
    Nishi, Shinichi
    KIDNEY INTERNATIONAL SUPPLEMENTS, 2013, 3 (05) : 457 - 461
  • [48] Chronic kidney disease - Mineral bone disorder
    Moe, Sharon M.
    PERITONEAL DIALYSIS INTERNATIONAL, 2008, 28 : S5 - S10
  • [49] Chronic kidney disease mineral bone disorder
    Pavlovic, Drasko
    Katicic, Dajana
    Gulin, Tonko
    Josipovic, Josipa
    Orlic, Lidija
    PERIODICUM BIOLOGORUM, 2015, 117 (01) : 81 - 85
  • [50] Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders
    Bover, Jordi
    Urena, Pablo
    Aguilar, Armando
    Mazzaferro, Sandro
    Benito, Silvia
    Lopez-Baez, Victor
    Ramos, Alejandra
    daSilva, Iara
    Cozzolino, Mario
    CALCIFIED TISSUE INTERNATIONAL, 2018, 103 (02) : 111 - 124